Efficacy and Safety of Electroconvulsive Therapy in the Treatment of Bipolar Disorder

2011 ◽  
Vol 27 (2) ◽  
pp. 153-164 ◽  
Author(s):  
Marcio Versiani ◽  
Elie Cheniaux ◽  
J. Landeira-Fernandez
2015 ◽  
Vol 17 (8) ◽  
pp. 892-901 ◽  
Author(s):  
Pierpaolo Medda ◽  
Cristina Toni ◽  
Federica Luchini ◽  
Michela Giorgi Mariani ◽  
Mauro Mauri ◽  
...  

2017 ◽  
Vol 33 (4) ◽  
pp. e40-e41 ◽  
Author(s):  
Laura Kranaster ◽  
Suna Su Aksay ◽  
Jan Malte Bumb ◽  
Christian Wisch ◽  
Michael Deuschle ◽  
...  

Medicine ◽  
2020 ◽  
Vol 99 (38) ◽  
pp. e22280
Author(s):  
Li Yang ◽  
Meili Yan ◽  
Li Du ◽  
Shasha Hu ◽  
Zhigang Zhang

2011 ◽  
Vol 27 (2) ◽  
pp. 123-126 ◽  
Author(s):  
Gian Paolo Minnai ◽  
Pier Giorgio Salis ◽  
Rosanna Oppo ◽  
Anna Paola Loche ◽  
Filomena Scano ◽  
...  

2021 ◽  
Vol 11 (73) (1) ◽  
pp. 226-233
Author(s):  
Simona Trifu ◽  
Elena Mănicu ◽  
Milu Petruţ ◽  
Adrian Nicu Lupu

Electroconvulsive therapy (ECT) generated many controversies over time. The clinical literature establishing the efficacy of ECT is among the most solid for any medical treatment, and has been extensively reviewed; however, both practitioners and patients seem to be still reluctant on this issue. In the following review we are aiming at raising the level of awareness among the interested parties regarding ECT. Epidemiological evidence shows that there are a growing number of cases in which ECT has a great benefit, among the most notable being pharmacological resistant depressive disorder, bipolar disorder, schizophrenia, catatonia and others. Current guidelines seem to be overly-prudent regarding ECT indications, in spite of a growing body of research attesting to its importance. Side effects of ECT range from somatic to cognitive and, with a careful prior examination, most are acute and can be managed in a few minutes. An exception to this is the cognitive impairment, which can last from a few hours to a few weeks and presents a reason to reconsider ECT in elderly patients with an important preexisting cognitive impairment.


2019 ◽  
Author(s):  
Xue Jiang ◽  
Qin Xie ◽  
Lian-Zhong Liu ◽  
Bao-Liang Zhong ◽  
Liang Si ◽  
...  

Abstract Background: To explore the clinical efficacy and safety of modified electroconvulsive therapy (MECT) in the treatment of elderly patients with refractory depression. Methods : A total of 43 older patients (18 male and 25 female) with refractory depression were enrolled in our study from March 2014 to February 2015, with the average age of 65±4.8 years old. Modified electroconvulsive therapy (MECT) was performed in these patients after physical examinations and anesthesia procedures. Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were used to assess the efficacy of MECT, and Wechsler Memory Scale (WMS) and mini mental state examination (MMSE) were used to evaluate the memory ability and cognitive function. The preoperative, intraoperative and postoperative care were conducted in patients accompanied by physical diseases. Results: The rate of efficacy was calculated as 67.44% after 4 weeks of MECT treatment. Our results showed HAMA and HAMD scores after 2 weeks of MECT treatment were significantly lower than that before treatment (P<0.05), and the differences were more significant after 4 weeks of MECT treatment (P<0.01). Compared with before treatment, the scores of memory quotient and immediate memory of WMS decreased significantly after 1 week of treatment (P<0.05). However, these events were not be presented with the progress of treatment, except for after 2 weeks of treatment. Our results demonstrated that compared with before treatment, the scores of MMSE significantly increased significantly after 4 weeks of treatment (P<0.05). There were no serious adverse events in all patients, including cardiovascular and cerebrovascular events. Among them, 7 patients had transient blood pressure rise and slight headache, which were relieved spontaneously after resting. Conclusion: MECT is an effective, well tolerated and safe method for the treatment of older patients with refractory depression, which is temporary and reversible for cognitive impairment. MECT can be recommended for the treatment of these patients after conducting effective risk control of comorbid somatic diseases.


We Walk ◽  
2020 ◽  
pp. 139-152
Author(s):  
Amy S. F. Lutz

This chapter describes electroconvulsive therapy (ECT) that stabilized Jonah's rapid-cycling bipolar disorder in 2010 after exhaustive medication trials, elaborate behavior plans, and a ten-month hospitalization failed. It details how Jonah experiences mild episodes of agitation with no obvious environmental triggers toward the end of the treatment interval. It also analyses the term “baseline,” which refers to an original, predisease state. The chapter describes Jonah's treatments that were therapeutic to the extent they restored optimal, baseline functioning. It discusses opponents of medicating children that are fierce and pervasive, such as in books with ominous titles like The Silenced Child and Suffer the Children, and certain articles featured on well-respected platforms.


Sign in / Sign up

Export Citation Format

Share Document